Chinese inhibitor drug candidate becomes first to enter phase
Chinese biotech company Jacobio Pharma announced on Monday that it had received approval from Chinese regulatory authorities for the registration phase-3 clinical trial of a combination therapy using its SHP2 inhibitor drug candidate JAB-3312.
SHP2 inhibitors are expected worldwide to have a substantial clinical effect in cancer and immunity disease treatment, and the approval made JAB-3312 the first SHP2 inhibitor to enter the phase-3 clinical study globally.
The approved clinical study in China is designed to evaluate the efficacy and safety of JAB-3312 in combination with the company's other investigational drug candidate KRAS G12C inhibitor glecirasib, for treating first-line non-small cell lung cancer patients with KRAS G12C mutations.
The control arm is the current standard treatment for first-line non-small cell lung cancer, which is the combination therapy of PD-1 antibody and chemotherapy.
Related articles
From flooding in Brazil and Houston to brutal heat in Asia, extreme weather seems nearly everywhere
In sweltering Brazil, worst-ever flooding killed dozens of people and paralyzed a city of about 4 mi2024-05-08Animation Featuring China's Sanxingdui Culture Set to Hit Big Screen
Contact Us HomeNewsHighlightACWF NewsSocietyWom2024-05-08Int'l Bicycles, Baby Strollers and Toys Fair Held in Hebei
Contact Us HomeNewsHighlightACWF NewsSocietyWom2024-05-08Liubao Tea Industry Thriving in Wuzhou, S China
Contact Us HomeNewsHighlightACWF NewsSocietyWom2024-05-08- In the emergency room, Dr Jordan Wagner, also known as Doctor ER, treats everything from gunshot tra2024-05-08
Museum of Grand Canal Culture to Open in Beijing
Contact Us HomeNewsHighlightACWF NewsSocietyWom2024-05-08
atest comment